Home World News EMA Recommends Granting a Marketing Authorisation for Tarlatamab World News EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 317 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research MOST POPULAR Additional Translations of the ESMO Patient Guides Now Available in the Croatian May 18, 2026 The Gift of Time December 8, 2023 ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... January 31, 2022 Lung-Sparing Surgery Is Effective for Some with Early-Stage Lung Cancer March 9, 2023 Load more HOT NEWS New Vaccine Stimulates Survivors’ Immune Systems to Keep Triple-Negative Cancer from... Mom Goes From Worried To Mortified After Finding Dark Brown Spot... PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments... FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer